Filing Flows › Krystal Biotech (KRYS) › Q3 2026
Krystal Biotech (KRYS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Krystal Biotech (KRYS) reported revenue of $127M for the third quarter 2026 (Q3 2026), +30% from a year earlier and +7% from the quarter before. Operating margin was 55.9%, net earnings $63.1M (49.5% of revenue).
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $127M | +7% | +30% |
| Operating profit | $71.1M | +22% | +72% |
| Net earnings | $63.1M | +15% | -21% |
| Operating cash flow | $91.2M | +22% | +130% |
| Free cash flow | $90.3M | +27% | +138% |
What changed
Revenue was $127.3M in Q3 2026, up 30% year over year and up 7% from the previous quarter.
Operating profit was $71.1M, a 55.9% margin (up 13.6 points year over year). Of the extra revenue versus Q3 2025, 101% reached operating profit, above the 42% margin then. Total costs fell 0% while revenue rose 30%. The fastest-growing cost line was Other operating costs (+77%). Net earnings were $63.1M, down 21% year over year. The effective tax rate was 21.3%.
Operating cash flow was $91.2M (up 130% year over year), 145% of net earnings. Non-cash charges added back $1.5M of depreciation and $13.9M of share-based compensation. Working capital and other items added $12.7M. Capital expenditures of $1.0M left free cash flow of $90.3M.
Questions
What was Krystal Biotech's revenue in the third quarter 2026?
Krystal Biotech (KRYS) reported revenue of $127M for the third quarter 2026 (Q3 2026), +30% from a year earlier and +7% from the quarter before.
Was Krystal Biotech profitable in the third quarter 2026?
Operating profit was $71.1M (55.9% of revenue) and net earnings $63.1M.
Source: Krystal Biotech 10-Q on SEC EDGAR.